Empagliflozin, a SGLT2 inhibitor, attenuates endothelial dysfunction and atherogenesis by inhibiting inflammatory responses in the vasculature and adipose tissue in diabetic apolipoprotein E-deficient
Event: ESC Congress 2019
Topic: Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis
Session: Vascular remodelling from capillaries to aorta
